Brief: Xspray Pharma Announces Positive Clinical Data For Drug Candidate HyNap-Sora

Xspray Pharma publ AB

18/02/2019 13:50

Feb 18 (Reuters) - XSpray Pharma AB (publ)  XSPRAY.ST :
    * XSPRAY PHARMA ANNOUNCES POSITIVE CLINICAL DATA FOR THE
DRUG
CANDIDATE HYNAP-SORA
    * RESULTS ARE POSITIVE AND STUDY ACHIEVED ITS PRIMARY
PURPOSE TO
SHOW INCREASED BIOAVAILABILITY COMPARED TO ORIGINATOR PRODUCT
    * VARIABILITY BETWEEN SUBJECTS IN AUC AND CMAX WAS REDUCED
TO HALF
VERSUS NEXAVAR FOR ONE OF HYNAP-SORA FORMULATIONS.
    * XSPRAY PHARMA - STUDY EXAMINED HYNAP-SORA'S
BIOAVAILABILITY
COMPARED TO SORAFENIB CANCER DRUG
    * BOTH INVESTIGATED HYNAP COMPOSITIONS DEMONSTRATED
SIGNIFICANTLY
INCREASED BIOAVAILABILITY
    * STUDY ALSO SHOWED REDUCED BETWEEN SUBJECT VARIABILITY.
    * VARIABILITY BETWEEN SUBJECTS IN AUC AND CMAX WAS REDUCED
TO HALF
COMPARED TO NEXAVAR FOR ONE OF HYNAP-SORA FORMULATIONS

Source text for Eikon:  ID:nWkr4lK5lS 
Further company coverage:  XSPRAY.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))